Evidence mapPaperPMID 41358655Full record

ArticleInvestigative ophthalmology & visual science2025

KLF10-IN-1 Attenuates RPE Cell Apoptosis and Experimental Diabetic Retinopathy Via the KLF10/PERK/eIF2α/ATF4/CHOP Pathway.

Weiwen Hu, Heng Yang, Qiqi Zhu, Guanghao Zheng, Jian Tan, Yeting Lin, Yicang Wang, Yahan Tu, Qiong Zhou

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiwen HuDepartment of Ophthalmology, The First Affiliated Hospital, Jiangxi medical college, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.
Heng YangDepartment of Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan Province, the People's Republic of China.
Qiqi ZhuDepartment of Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.
Guanghao ZhengDepartment of Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.
Jian TanDepartment of Ophthalmology, the Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province, the People's Republic of China.
Yeting LinDepartment of Ophthalmology, The First Affiliated Hospital, Jiangxi medical college, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.
Yicang WangDepartment of Ophthalmology, The First Affiliated Hospital, Jiangxi medical college, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.
Yahan TuDepartment of Ophthalmology, The First Affiliated Hospital, Jiangxi medical college, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.
Qiong ZhouDepartment of Ophthalmology, The First Affiliated Hospital, Jiangxi medical college, Nanchang University, Nanchang, Jiangxi Province, the People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the roles of Krüppel-like factor 10 (KLF10) and its inhibitor KLF10-IN-1 in regulating high-glucose/hypoxia-induced RPE cell apoptosis and their involvement in diabetic retinopathy (DR). Methods: A DR mouse model was established using a high-fat, high-glucose diet and streptozotocin. An RPE cell model of high-glucose/hypoxia injury was constructed by culturing cells under high-glucose (30 mM) conditions in the presence of cobalt chloride (200 µM). KLF10 expression, apoptosis, and endoplasmic reticulum (ER) stress levels were assessed. KLF10 expression was modulated with small interfering RNA and overexpression plasmids. Dual luciferase reporter assays were used to evaluated the regulatory effect of KLF10 on PERK. The PERK pathway was activated by CCT020312 and inhibited by GSK2606414 for rescue experiments. The protective effects of KLF10-IN-1 were validated in vitro and in vivo. Results: KLF10 was highly expressed in RPE cells in DR model mice. After 48 hours of high-glucose/hypoxia exposure, hypoxia, inflammation, ER stress, and apoptosis were significantly exacerbated, accompanied by KLF10 upregulation. KLF10 knockdown suppressed apoptosis and ER stress, whereas KLF10 overexpression had the opposite effect. Western blotting confirmed KLF10 regulated PERK phosphorylation, and dual luciferase assays revealed that KLF10 transcriptionally activates PERK. KLF10 mediated apoptosis through the PERK/eIF2α/ATF4/CHOP pathway. Inhibiting this pathway with KLF10-IN-1 reduced high-glucose/hypoxia-induced damage to RPE cells and ameliorated retinal damage in diabetic mice. Conclusions: KLF10 is upregulated in DR model mice and high-glucose/hypoxia-exposed RPE cells and modulates apoptosis and ER stress through the PERK/eIF2α/ATF4/CHOP pathway. KLF10-IN-1 has protective effects, suggesting its potential for early DR treatment.

Indexed as

Activating Transcription Factor 4ApoptosisDiabetic RetinopathyeIF-2 KinaseGene Expression RegulationKruppel-Like Transcription FactorsRetinal Pigment EpitheliumAnimalsBlotting, WesternCells, CulturedDiabetes Mellitus, ExperimentalDisease Models, AnimalEndoplasmic Reticulum StressEukaryotic Initiation Factor-2MaleMiceActivating Transcription Factor 4Atf4 protein, mouseDdit3 protein, mouseeIF-2 KinaseEukaryotic Initiation Factor-2Kruppel-Like Transcription FactorsTranscription Factor CHOP

Identifiers

PMID41358655
PMCPMC12700178

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.